Consistently, the tumor-infiltrating CD8+ T cells isolated from RSL-treated tumors significantly inhibited the proliferation of MC-38 tumor cells compared with the CD8+ T cells isolated from the PBS, anti-PD-1 and RSL groups, indicating the higher cytotoxic capability of CD8+ T cells after RSL treatment (Figure 6C). This evidence concerns the gene PDCD1 and neoplasm.